Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,477 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin Dependent Diabetes Mellitus 1 Clear all
Completed Not applicable Interventional Results available

Technology-delivered Physical Activity Program for Adolescents With Type 1 Diabetes

NCT05319600
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Diabetes behavior change skills training, Physical activity promotion program
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
13 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 16, 2026, 9:07 AM EDT
Completed No phase listed Observational

Characteristics of Persons With an Eating Disorder and Type 1 Diabetes

NCT00945711
View directory record Official record
Conditions
Eating Disorder, Type 1 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
Not listed
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Not applicable Interventional Results available

Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes

NCT04545567
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
RocketAP, USS Virginia
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 16, 2026, 9:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

NCT05626712
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions
CELZ-201 Administration, Control Group
Biological · Other
Lead sponsor
Creative Medical Technology Holdings Inc
Industry
Eligibility
18 Years to 35 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 16, 2026, 9:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574
View directory record Official record
Conditions
Type 1 Diabetes, New Onset
Interventions
Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
9 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Not applicable Interventional Results available

Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study

NCT05014789
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Control-IQ technology 2.0
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
14 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

NCT00206297
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Phase 3 Interventional Results available

Liraglutide In Overweight Patients With Type 1 Diabetes

NCT01753362
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
liraglutide, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Not applicable Interventional Results available

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

NCT01684943
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Multiplex pharmacokinetic profiling, Continuous insulin monitoring
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 16, 2026, 9:07 AM EDT
Recruiting Not applicable Interventional

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

NCT06852950
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Type 1 Diabetes Mellitus (T1DM), Hyperglycemia
Interventions
Libre 3 Plus Continuous Glucose Monitor, Dexcom G7 Continuous Glucose Monitor
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Phase 1Phase 2 Interventional

Acetazolamide in Persons With Type 1 Diabetes - Dose Finding

NCT05473364
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acetazolamide
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Reversing Type 1 Diabetes After it is Established

NCT01106157
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-Thymocyte Globin (ATG), Placebo, Pegylated GCSF
Drug
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics

NCT00607230
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BCG, Saline
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 16, 2026, 9:07 AM EDT
Completed No phase listed Observational

Adipose Tissue Function After Pancreas Transplantation

NCT01729130
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions
Adipose tissue biopsy
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

NCT02735044
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Not applicable Interventional

Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus

NCT00187564
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
controlled-release oral alpha-lipoic acid
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 16, 2026, 9:07 AM EDT
Recruiting Not applicable Interventional

Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes

NCT05540704
View directory record Official record
Conditions
Type 1 Diabetes, Eating Disorders, Disordered Eating Behaviors, Purging (Eating Disorders), Binge-Eating Disorder
Interventions
ACT, Supportive Diabetes Counseling
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 50 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 16, 2026, 9:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

To Evaluate if Wide Blood Sugar Fluctuations Lead to Injury of Heart Function and Heart Nerves

NCT01170832
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Not applicable Interventional

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3

NCT00742521
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
glucose clamp
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 16, 2026, 9:07 AM EDT
Completed No phase listed Observational

Diabetes Attitudes Wishes and Needs

NCT01507116
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Relatives to/Carers of Patients, Healthcare Professionals
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
8,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 16, 2026, 9:07 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Liver Glycogen and Hypoglycemia in Humans

NCT03241706
View directory record Official record
Conditions
Hypoglycemia; Iatrogenic
Interventions
Low Fructose, Saline, Somatostatin, Insulin, Glucagon, Dextrose solution, High Fructose
Drug
Lead sponsor
Jason Winnick
Other
Eligibility
21 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 16, 2026, 9:07 AM EDT
Completed Phase 4 Interventional Results available

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

NCT01526733
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 16, 2026, 9:07 AM EDT
Active, not recruiting No phase listed Observational

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

NCT03945747
View directory record Official record
Conditions
Type1 Diabetes Mellitus, Diabetes Mellitus, Type 1, Autoimmune Diabetes, Juvenile Diabetes, Diabetes Mellitus Complication, Diabetic Nephropathies, Metabolic Disease, Diabetic Kidney Disease
Interventions
Blood draw, Urine sample collection, DXA scan
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 16, 2026, 9:07 AM EDT